SCHEMBL4570233

SCHEMBL4570233

O=C(N/N=C/c1cccc(O)c1O)c1cc2ccccc2cc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.76
ECE2 P0DPD6 2/20 0.72
ECE1 P42892 2/20 0.72
MUS81 Q96NY9 2/20 0.72
GAA P10253 3/20 0.69
MGAM O43451 2/20 0.69
SI P14410 2/20 0.69
MGAM2 Q2M2H8 2/20 0.69
SIRT1 Q96EB6 1/20 0.68
FTO Q9C0B1 1/20 0.68
PGR P06401 1/20 0.66
DNM1 Q05193 1/20 0.63
MAPT P10636 1/20 0.63
RECQL P46063 1/20 0.63
NOX4 Q9NPH5 1/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1175103 0.91 AR (0.82) ARECE2ECE1MUS81GAA
SCHEMBL12868822 0.91 AR (0.82) ARECE2ECE1MUS81GAA
SCHEMBL1175104 0.91 AR (0.82) ARECE2ECE1MUS81GAA
SCHEMBL29874298 0.91 AR (0.82) ARECE2ECE1MUS81GAA
SCHEMBL4570237 0.90 AR (0.76) ARECE2ECE1MUS81GAA
SCHEMBL14976907 0.89 AR (0.70) ARECE2ECE1MUS81GAA
SCHEMBL14983737 0.89 AR (0.70) ARECE2ECE1MUS81GAA
SCHEMBL14976908 0.89 AR (0.70) ARECE2ECE1MUS81GAA
SCHEMBL14983734 0.89 AR (0.70) ARECE2ECE1MUS81GAA
SCHEMBL21145720 0.89 MGAM (0.65) ARECE2ECE1MUS81GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2911692-B1 USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY UNIV QUEENSLAND (AU) 2019-08-21 EP disclosed
US-10253107-B2 Use of endocytosis inhibitors and antibodies for cancer therapy THE UNIVERSITY OF QUEENSLAND (AU) 2019-04-09 US disclosed
US-9296716-B2 Androgen receptor ligands THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2016-03-29 US disclosed
US-9296716-B2 Androgen receptor ligands THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2016-03-29 US disclosed
US-20150284469-A1 USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY THE UNIVERSITY OF QUEENSLAND (AU) 2015-10-08 US disclosed
US-20150284469-A1 USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY THE UNIVERSITY OF QUEENSLAND (AU) 2015-10-08 US disclosed
US-20140357682-A1 ANDROGEN RECEPTOR LIGANDS The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) 2014-12-04 US disclosed
US-20140357682-A1 ANDROGEN RECEPTOR LIGANDS The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) 2014-12-04 US disclosed
US-8809386-B2 Use of dynamin ring stabilizers CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) 2014-08-19 US disclosed
US-8809386-B2 Use of dynamin ring stabilizers CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) 2014-08-19 US disclosed
WO-2013076275-A1 ANDROGEN RECEPTOR LIGANDS THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIV.TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) 2013-05-30 WO disclosed
US-20120122968-A1 USE OF DYNAMIN RING STABILIZERS THE GENERAL HOSPITAL CORPORATION (US) 2012-05-17 US disclosed
US-20120122968-A1 USE OF DYNAMIN RING STABILIZERS THE GENERAL HOSPITAL CORPORATION (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10253107-B2 Use of endocytosis inhibitors and antibodies for cancer therapy CLINT1, CLTC, DNM1L AR 3432/4885ECE2 1743/4885ECE1 869/4885
US-20150284469-A1 USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY CLINT1, CLTC, DNM1L AR 3432/4885ECE2 1743/4885ECE1 869/4885
US-20140357682-A1 ANDROGEN RECEPTOR LIGANDS AR, NR5A1, SHBG AR 1/4885ECE2 3648/4885ECE1 3442/4885
US-20120122968-A1 USE OF DYNAMIN RING STABILIZERS DNM1L, DNM1, DNM2 AR 4768/4885ECE2 1084/4885ECE1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.